Form 4: DYNVAX CFO MacDonald Sees Accelerated Vesting Amid Sanofi Merger
Insider Transaction Report
DYNAVax Technologies' SVP and CFO, Kelly MacDonald, reported accelerated vesting of performance and restricted stock units tied to the company's merger agreement with Sanofi.
Summary
- Kelly MacDonald, SVP and CFO of DYNAVax Technologies Corp (DVAX), reported transactions related to the acceleration of vesting of performance-based restricted stock units (PSUs) and restricted stock units (RSUs).
- The acceleration was approved by the Board of Directors on December 23, 2025, in connection with an Agreement and Plan of Merger between DYNAVax, SANOFI, and Samba Merger Sub, Inc.
- PSUs, representing 125% of the target number, were earned due to the achievement of the rTSR performance condition over a shortened period, with the Issuer's total stockholder return determined by the merger agreement price of $15.50 per share.
- MacDonald acquired 37,500 shares from PSUs and 29,618 shares from RSUs (15,477 + 14,141).
- 36,141 shares were withheld by the Issuer to satisfy tax withholding requirements on the vesting of PSUs and RSUs, at a price of $15.38 per share.
- Following these transactions, MacDonald beneficially owns 60,204 shares of common stock directly.
Sentiment
Score: 8
Explanation: The filing reports accelerated vesting of executive equity awards at 125% of target due to a merger agreement, indicating a positive outcome for the executive and the company's performance leading to the acquisition. The merger price of $15.50 per share is a clear positive for shareholders.
Positives
- Acceleration of vesting for PSUs and RSUs for the SVP and CFO.
- PSUs were earned at 125% of the target number, indicating strong performance relative to an indexed group of companies (rTSR).
- The merger agreement values DYNAVax common stock at $15.50 per share.
Negatives
- 36,141 shares were withheld to cover tax obligations, reducing the net shares received by the reporting person.
Future Outlook
The filing indicates that DYNAVax Technologies is in the process of being acquired by SANOFI, with an Agreement and Plan of Merger dated December 23, 2025. This suggests the company will cease to be an independent publicly traded entity upon completion of the merger.
Management Comments
- The Board of Directors approved acceleration of vesting of certain performance-based restricted stock units and restricted stock units previously granted to the Reporting Person, effective as of the Effective Date of the Merger Agreement.
- The Board determined that PSUs (representing 125% of target) were earned according to achievement of the rTSR performance condition over a shortened performance period, with the Issuer's total stockholder return determined based on the merger agreement price of $15.50.
Industry Context
This announcement signifies a consolidation event within the biotechnology or pharmaceutical sector, with a larger entity (Sanofi) acquiring a smaller one (DYNAVax Technologies). Such mergers often occur to expand product pipelines, gain market share, or acquire specific technologies. The accelerated vesting for executives is a common provision in merger agreements to ensure executive retention and alignment during the transition.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Approval | The Board of Directors approved the acceleration of vesting for certain performance-based restricted stock units (PSUs) and restricted stock units (RSUs) for Kelly MacDonald, SVP and CFO, effective December 23, 2025. | December 23, 2025 | This action aligns executive incentives with the merger outcome and provides immediate liquidity for vested equity, a common practice in change-of-control events. |
| Performance Condition Determination | The Board determined that PSUs were earned at 125% of the target number based on the achievement of the rTSR performance condition over a shortened period, using the merger agreement price of $15.50 per share. | December 23, 2025 | This confirms the company's strong performance relative to its peers, as evaluated by the Board, leading up to the merger. |
Related Party Transactions
- The Agreement and Plan of Merger between DYNAVax Technologies, SANOFI, and Samba Merger Sub, Inc.
- Acceleration of vesting of PSUs and RSUs for SVP and CFO Kelly MacDonald, directly linked to the merger agreement.
- Withholding of shares by the Issuer to satisfy tax obligations on vested equity awards.
Stakeholder Impact
- Shareholders: Will receive $15.50 per share for their common stock upon completion of the merger.
- Executive (Kelly MacDonald): Benefits from accelerated vesting of equity awards and the achievement of performance targets at 125%, providing immediate liquidity.
Next Steps
- Completion of the merger between DYNAVax Technologies and SANOFI.
Key Dates
| Date | Description |
|---|---|
| February 15, 2024 | Grant date for a portion of RSUs, originally scheduled to vest over three years. |
| February 13, 2025 | Grant date for another portion of RSUs, originally scheduled to vest over three years. |
| December 23, 2025 | Effective Date of the Agreement and Plan of Merger with SANOFI; Board of Directors approved acceleration of vesting for PSUs and RSUs. |
| December 24, 2025 | Date shares were withheld for tax purposes. |
| December 29, 2025 | Date the Form 4 was signed. |
| December 31, 2025 | Original end of performance period for rTSR PSUs. |
Keywords
DYNAVax Technologies, DVAX, Sanofi, Merger, Acquisition, SEC Form 4, Insider Trading, Restricted Stock Units, Performance Stock Units, Executive Compensation, Stock Vesting, Kelly MacDonald, SVP CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.